SynthesisNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2023
Dose-response relationships of LSD-induced subjective experiences in humans.
Synthesis in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants.Translational psychiatry · 2024Trial
- Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings.International journal of methods in psychiatric research · 2026Article
- Phenomenology of Psychedelic Experiences and Psychedelic-Associated Distressing Effects: Quantifying Subjective Experiences.Current topics in behavioral neurosciences · 2026Review
- Body image phenomenology in reports of psychedelic and meditative experiences: main themes and associations with body attitudes.Neuroscience of consciousness · 2026Article
- Classifying Psychedelic-Related Complications.Current topics in behavioral neurosciences · 2026Review
- Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics.Current topics in behavioral neurosciences · 2026Review
- Applying the EU Regulatory Framework to Determine the Benefit-Risk Profile of Psychedelics.ACS pharmacology & translational science · 2025Article
- Ketamine-Occasioned Mystical Experience in Veterans with Treatment-Resistant Depression: A Retrospective Exploratory Analysis.Psychedelic medicine (New Rochelle, N.Y.) · 2025Article
- The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics.Journal of psychopharmacology (Oxford, England) · 2025Article
- Decreased COCommunications psychology · 2025Article
- Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use.PNAS nexus · 2025Article
- Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Thalamocortical interactions reflecting the intensity of flicker light-induced visual hallucinatory phenomena.Network neuroscience (Cambridge, Mass.) · 2025Article
- Microbiome: The Next Frontier in Psychedelic Renaissance.Journal of xenobiotics · 2023Review
- Flicker light stimulation induces thalamocortical hyperconnectivity with LGN and higher-order thalamic nuclei.Imaging neuroscience (Cambridge, Mass.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lysergic acid diethylamide (LSD) is a potent classic serotonergic psychedelic, which facilitates a variety of altered states of consciousness. Here we present the first meta-analysis establishing dose-response relationship estimates of the altered states of consciousness induced by LSD. Data extracted from articles identified by a systematic literature review following PRISMA guidelines were obtained from the Altered States Database. The psychometric data comprised ratings of subjective effects from standardized and validated questionnaires: the Altered States of Consciousness Rating Scale (5D-ASC, 11-ASC) and the Mystical Experience Questionnaire (MEQ30). We performed meta-regression analyses using restricted cubic splines for data from studies with LSD doses of up to 200 μg base. Most scales revealed a sigmoid-like increase of effects, with a plateauing at around 100 μg. The most strongly modulated factors referred to changes in perception and illusory imagination, followed by positively experienced ego-dissolution, while only small effects were found for Anxiety and Dread of Ego Dissolution. The considerable variability observed in most factors and scales points to the role of non-pharmacological factors in shaping subjective experiences. The established dose-response relationships may be used as general references for future experimental and clinical research on LSD to compare observed with expected subjective effects and to elucidate phenomenological differences between psychedelics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.